SCHEMBL25855629

SCHEMBL25855629

OCC1CCCN(c2ccc(O)cc2)C1

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 6/20 0.45
ESR2 Q92731 6/20 0.45
CYP3A4 P08684 3/20 0.45
CYP2C9 P11712 2/20 0.45
CYP2D6 P10635 2/20 0.45
MAP4K4 O95819 1/20 0.43
SYK P43405 2/20 0.42
JAK2 O60674 1/20 0.42
TYMP P19971 2/20 0.42
PTPN1 P18031 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
CYP2C19 P33261 1/20 0.40
KHK P50053 1/20 0.40
POLB P06746 1/20 0.40
HTT P42858 1/20 0.40
KMT2A Q03164 1/20 0.40
CDK8 P49336 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7146014 0.85 CYP3A4 (0.56) CYP3A4MAP4K4SYKJAK2TYMP
SCHEMBL21135496 0.85 NOTUM (0.49) CYP2D6MAP4K4SYKJAK2TYMP
SCHEMBL77035 0.85 KDM4E (0.49) ESR2CYP3A4CYP2D6MAP4K4SYK
SCHEMBL6271445 0.85 NOTUM (0.49) CYP2D6MAP4K4SYKJAK2TYMP
SCHEMBL21135575 0.85 CYP3A4 (0.56) CYP3A4MAP4K4SYKJAK2TYMP
SCHEMBL7790528 0.85 EPHX2 (0.51) CYP2D6MAP4K4SYKJAK2TYMP
SCHEMBL21135458 0.85 NOTUM (0.49) CYP2D6MAP4K4SYKJAK2TYMP
SCHEMBL21135466 0.85 CYP3A4 (0.56) CYP3A4MAP4K4SYKJAK2TYMP
SCHEMBL21135739 0.85 CYP2D6 (0.52) CYP2D6MAP4K4TYMPPTPN1POLB
SCHEMBL21135447 0.85 CYP2D6 (0.52) CYP2D6MAP4K4TYMPPTPN1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230212158-A1 SMALL MOLECULE INHIBITORS OF GALECTIN-3 BRISTOL MYERS SQUIBB CO (US) 2023-07-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230212158-A1 SMALL MOLECULE INHIBITORS OF GALECTIN-3 LGALS3, LGALS1, LGALS3BP ESR1 4699/4885ESR2 3523/4885CYP3A4 4307/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.